Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment, with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development ...

On cloning the gene encoding glucagon, they discovered that it also encoded a related hormone, which scientists would later call GLP-1. 2 Around the same time, scientists determined the sequences of ...

The incretin effect is impaired in patients with Type 2 diabetes. Exogenous administration of GLP-1 stimulates insulin secretion, inhibits glucagon secretion, slows gastric emptying, decreases ...